Key Highlights

  • Estrella Immunopharma, Inc. (NASDAQ:ESLA) rose about 8.63% to USD 1.07 in early trading on Monday, October 26, 2026, back above USD 1.00 from a prior close of about USD 0.985.
  • The company has not issued a release explaining the move; its latest updates are the fifth trial site on Wednesday, October 14, 2026 and the first two-infusion patient on Thursday, October 15, 2026.
  • The shares rose 68.35% on October 14 and fell 19.66% on October 15, which shows how volatile the stock is, with a market capitalisation near USD 42.8 million.
  • Phase I data in February 2026 showed a 100% complete response rate at Month 1 in the high-dose cohort of nine patients, with no treatment-related serious adverse events.

A Rebound Above USD 1.00 Without New Data

Estrella Immunopharma, Inc. (NASDAQ:ESLA) rose about 8.63% to USD 1.07 in early trading on Monday, October 26, 2026, after a prior close of about USD 0.985, and the company has not issued a release explaining the move. The clinical-stage company develops EB103, a CAR-T cell therapy for B-cell non-Hodgkin lymphoma, in the STARLIGHT-1 Phase I/II trial. On Wednesday, October 14, 2026 it activated a fifth site, Intermountain Health LDS Hospital in Salt Lake City, and the shares rose 68.35%. On Thursday, October 15, 2026 it reported the first patient given two infusions at the recommended Phase II dose, and the shares fell 19.66%.

Why Small Biotech Shares Move on Trial Milestones

CAR-T therapy modifies a patient's own T cells to attack cancer, and early data for such products drive valuations of small developers. Estrella Immunopharma, Inc. (NASDAQ:ESLA) reported on Monday, February 9, 2026 that nine patients in the Phase I high-dose cohort reached a 100% complete response rate at Month 1, with durations of 3 to 18 months. The expansion phase now tests two infusions three weeks apart at 5 million T cells per kilogram, reported without treatment-related serious adverse events in the first month. With a float of about 17.22 million shares, trial site news and rebounds from below USD 1.00 can produce large moves, as the October 14 and October 15 sessions showed.

Risks and What to Watch

The first risk for Estrella Immunopharma, Inc. (NASDAQ:ESLA) is clinical, since early responses in small cohorts may not hold in larger trials. The second is funding: a company with a market capitalisation near USD 42.8 million will probably need to raise capital, and equity issuance would dilute holders. The third is listing compliance, as a close below USD 1.00 on Friday, October 23, 2026 raises the risk of a bid price notice if it persists. Investors should watch the Federal Reserve decision on Wednesday, October 28, 2026, further site activations and patient data from STARLIGHT-1, and any financing announcement or exchange notice.

Where Things Stand

The answer is that Estrella Immunopharma, Inc. (NASDAQ:ESLA) rose about 8.63% as a rebound above USD 1.00 after a volatile fortnight of trial milestones, since the company has issued no release for Monday. Early response data remain encouraging but come from small cohorts. The next catalysts are the Federal Reserve decision on Wednesday, October 28, 2026 and further STARLIGHT-1 site or patient updates. Clinical outcomes are uncertain, funding may dilute holders, and this is not investment advice.